← Back to Search

Other

Oral TACH101 for Cancer

Phase 1
Waitlist Available
Research Sponsored by Tachyon Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1
Participant must be 18 years of age or older
Must not have
Significant cardiovascular disease including myocardial infarction, uncontrolled angina, congestive heart failure, prolonged QT interval, significant ventricular arrhythmias, heart block, uncontrolled hypertension
Any ongoing anticancer therapy, clinically significant active infections, history of HIV, hepatitis B, or hepatitis C
Timeline
Screening 3 weeks
Treatment Varies
Follow Up lead-in day 1 to end of treatment (up to approximately 204 days)
Awards & highlights

Summary

This trial is testing a new oral medication called TACH101 in patients with advanced and metastatic solid tumors. Researchers aim to find the best dose that patients can handle and see if it can shrink or stop the tumors. They are also checking how safe the medication is for these patients.

Who is the study for?
This trial is for adults with advanced or metastatic solid tumors, including gastrointestinal cancers and MSI-H colorectal cancer that didn't respond to standard treatments. Participants must have measurable disease, be in good physical condition (ECOG score 0-1), and meet specific blood count and organ function criteria. Women of childbearing potential must test negative for pregnancy and agree to use contraception.
What is being tested?
The study tests TACH101's safety, tolerability, dosage levels, how the body processes it, and its effectiveness against tumors. It has two parts: Phase 1a finds the highest dose patients can take without serious side effects; Phase 1b determines a recommended dose for future studies based on responses from participants.
What are the potential side effects?
While specific side effects of TACH101 are not listed here, common ones in trials like this may include nausea, fatigue, diarrhea, liver enzyme changes leading to potential liver damage or inflammation issues affecting other organs.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am fully active or can carry out light work.
Select...
I am 18 years old or older.
Select...
My advanced cancer can be measured by standard criteria.
Select...
I have recovered from side effects of previous treatments, except for hair loss or appetite loss.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I do not have serious heart conditions like heart attacks, uncontrolled high blood pressure, or irregular heartbeats.
Select...
I am not currently on cancer treatment and do not have HIV, hepatitis B, or C.
Select...
I have liver or kidney disease.
Select...
I have not had major surgery in the last 2 months.
Select...
I have received a stem cell transplant from a donor.
Select...
I have or might have cancer spread to my brain.
Select...
I have not had surgery to remove my stomach or upper bowel, nor do I have a digestive condition that affects drug absorption.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~lead-in day 1 to end of treatment (up to approximately 204 days)
This trial's timeline: 3 weeks for screening, Varies for treatment, and lead-in day 1 to end of treatment (up to approximately 204 days) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Phase 1a Dose Escalation: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Phase 1b Dose Expansion: Number of Participants With TEAEs

Trial Design

2Treatment groups
Experimental Treatment
Group I: Phase 1b: Dose ExpansionExperimental Treatment1 Intervention
In Phase 1b, participants will receive TACH101 at the RP2D identified in Phase 1a. Two cohorts of participants will be enrolled: * Participants with gastrointestinal cancers. * Participants with high microsatellite instability (MSI-H) metastatic colorectal cancer (CRC).
Group II: Phase 1a: Dose EscalationExperimental Treatment1 Intervention
In Phase 1a, participants will receive TACH101 in a 48 hour lead in period followed by repeated dosing at different dosing regimens in each 28 day cycle.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for solid tumors include targeted therapies, immunotherapies, and traditional chemotherapies. Targeted therapies, like TACH101, work by specifically inhibiting molecular pathways essential for tumor growth and survival, thereby minimizing damage to normal cells. Immunotherapies enhance the body's immune system to recognize and attack cancer cells, offering a more personalized treatment approach. Traditional chemotherapies kill rapidly dividing cells but can affect both cancerous and healthy cells. Understanding these mechanisms is crucial for solid tumor patients as it helps in selecting the most effective treatment with the least side effects, improving overall outcomes and quality of life.
Current trends and future directions in the genetic therapy of human neoplastic disease.Genetically engineered mouse models: closing the gap between preclinical data and trial outcomes.

Find a Location

Who is running the clinical trial?

Tachyon Therapeutics, Inc.Lead Sponsor

Media Library

TACH101 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05076552 — Phase 1
Solid Tumors Research Study Groups: Phase 1a: Dose Escalation, Phase 1b: Dose Expansion
Solid Tumors Clinical Trial 2023: TACH101 Highlights & Side Effects. Trial Name: NCT05076552 — Phase 1
TACH101 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05076552 — Phase 1
~9 spots leftby Jul 2025